Mirion Technologies, Inc (MIR)
OrangeHealth Care · As of 17 July 2026
Price chart — 52 weeks
OakBag’s model puts the fair value of Mirion Technologies, Inc (MIR) at about $35.13, against a recent price of $15.97 — a margin of safety of ≥ +55%. On that basis the traffic light is set so it looks fairly valued. The estimate blends up to 4 independent valuation methods and is benchmarked against other Health Care names. It is a model estimate for research, not a price target or a recommendation.
Fair value vs. price
- Current price
- $15.97
- Estimated fair value
- $35.13
- Margin of safety
- ≥ +55%
How the fair value is built
Why not green?
- Every valuation method came in far above the price and was capped by the model's outlier guard — with no independent method confirming it, the discount isn't trusted.
Knock-out safety checks passed
- Bankruptcy risk (Altman Z″)
- Negative equity
- Excessive leverage
- Illiquid
- Penny / micro-cap
- Stale fundamentals
- Piotroski F-score
- 8 / 9
- Altman Z-score
- 5.18
- Beneish M-score
- -2.29
Quality & factor profile
See the full analysis
Create a free OakBag account to unlock every valuation method, price history, watchlists and email alerts for MIR and 1,850+ other stocks.
No credit card · just an email
Frequently asked questions
Is Mirion Technologies (MIR) undervalued?
On OakBag’s model, Mirion Technologies, Inc looks fairly valued: the estimated fair value is $35.13 versus a recent price of $15.97, a margin of safety of ≥ +55%. This is a model estimate, not investment advice.
What is MIR’s fair value estimate?
OakBag estimates Mirion Technologies, Inc’s fair value at about $35.13, blending up to 4 methods — peer P/E, price-to-book, peer EV/EBITDA, a machine-learning valuation and a cash-flow DCF — clipped to a sensible band and taken at the median.
What is margin of safety?
Margin of safety is how far below the estimated fair value the price sits: (fair value − price) ÷ fair value. Here it is ≥ +55%. A positive number means the model sees the stock as cheap; OakBag only turns a stock green above +15%.
Does a green verdict mean I should buy MIR?
No. OakBag is an educational and research tool, not investment advice. The traffic light is an automated model output based on third-party data that may be delayed or inaccurate. Always do your own research.
Other Health Care stocks
An educational and research tool — not investment advice. OakBag is an educational and research tool, not investment advice. Scores and rankings are automated model outputs based on third-party data and may be inaccurate or delayed. Nothing here is a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal.